Quanterix said on Monday it has inked a non-exclusive agreement with Brigham and Women's Hospital for a SARS-CoV-2 serology test on its Simoa multiplex immunoassay platform.

People of different ancestral backgrounds can have different DNA methylation, mRNA, and microRNA expression levels

Castle Biosciences reported after the close of the market on Monday that it doubles its first quarter revenues year over year.

10x Genomics reported after the close of the market on Monday a 34 percent increase in first quarter revenues.

Researchers have isolated a coronavirus from Malayan pangolins that is highly similar to SARS-CoV-2, suggesting pangolins may have served as an intermediate host for the virus.

Grifols Diagnostic Solutions announced Thursday its Procelix Panther System featuring Automation Ready Technology (ART) received approval from the US Food and Drug Administration.

Guardant Health reported after the close of the market on Thursday that its first quarter 2019 revenues were up 84 percent year over year.

Grail said today that it has raised $390 million in a Series D financing round, which included new investors Public Sector Pension Investment Board, Canada Pension Plan Investment Board, and two other undisclosed contributors.

The company is recalling three lots of Nizatidine Oral Solution, 15 mg/mL (75 mg/5mL) due to potential N-Nitrosodimethylamine (NDMA) contamination.

The company is recalling Tetracycline HCl Capsules USP, 250 mg and 500 mg, 100-count bottles because of failed dissolution specifications.

Arch Venture Partners, an investment company headquartered in Chicago, IL, announced on April 2, 2020 that it closed two new funds

Alnylam Pharmaceuticals, an RNA interference (RNAi) therapeutics company located in Cambridge, MA, and Blackstone Life Sciences, a private investment platform

The novel coronavirus pandemic has presented the global pharma industry with a double challenge: to develop potential treatments and preventative vaccines, and continue to meet the existing needs of healthcare providers and patients

Moderna, a clinical stage biotechnology company headquartered in Cambridge, MA, announced on April 16, 2020 that the Biomedical Advanced Research and Development Authority (BARDA)

4D pharma to Launch Phase-II Study of Biotherapeutic Product for COVID-19 Treatment